Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02520778
Recruitment Status : Recruiting
First Posted : August 13, 2015
Last Update Posted : February 21, 2019
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)

Tracking Information
First Submitted Date  ICMJE August 10, 2015
First Posted Date  ICMJE August 13, 2015
Last Update Posted Date February 21, 2019
Actual Study Start Date  ICMJE March 31, 2016
Estimated Primary Completion Date July 30, 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: January 25, 2019)
  • Incidence of toxicity (Dose escalation) [ Time Frame: Up to 2 years ]
    Incidence of toxicity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5
  • Feasibility of the combination therapy in T790M+ lung cancer (Dose expansion) [ Time Frame: Up to 12 weeks (3 courses of treatment) ]
    Will be measured as at least 50% of patients achieving the expected dose duration and intensity. The proportion of patients completing 3 courses of therapy with > 75% of total dose of each drug will be quantified. The combination dosing will be considered potentially feasible if at least 50% of patients achieve the expected dose duration and intensity (95% confidence interval 30%-70%).
Original Primary Outcome Measures  ICMJE
 (submitted: August 10, 2015)
  • Feasibility of the combination therapy in T790M+ lung cancer, measured as at least 50% of patients achieving the expected dose duration and intensity (Dose expansion) [ Time Frame: Up to 12 weeks (3 courses of treatment) ]
    The proportion of patients completing 3 courses of therapy with > 75% of total dose of each drug will be quantified. The combination dosing will be considered potentially feasible if at least 50% of patients achieve the expected dose duration and intensity (95% confidence interval 30%-70%).
  • Incidence of toxicity, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 (Dose escalation) [ Time Frame: Up to 2 years ]
Change History Complete list of historical versions of study NCT02520778 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: January 25, 2019)
  • Pharmacokinetics parameters (maximum observed plasma drug concentration, area-under-the concentration-time-curve, Trough drug concentration at steady state, and half-life) of osimertinib in combination with navitoclax [ Time Frame: Pre-dose, 1, 2, 4, 6, and 8 hours after navitoclax administration (day 1 of courses 1 and 2) ]
    Pharmacokinetic calculations will incorporate consideration of the dosing change in navitoclax between the two measurement days.
  • Objective response rate [ Time Frame: Baseline up to 30 days after completion of study drug ]
    Will be assessed by Response Evaluation Criteria in Solid Tumors (RECIST). Calculated in the 20 patient expansion cohort and compared to the expected response rate of 61% in T790M+ lung cancer.
  • Change in plasma concentration of EGFR T790M and other EGFR mutations [ Time Frame: Baseline to up to 2 years ]
    Change in plasma concentration of EGFR T790M and other EGFR mutations will be studied in an exploratory fashion and compared to tumor response on imaging.
  • Biomarkers of apoptosis such as BCL2-like 1 (BCL-XL) and BCL2-like 11 (apoptosis facilitator) (BIM) levels in tumor tissue [ Time Frame: Baseline ]
    Biomarkers of apoptosis such as BCL-XL and BIM levels will be measured in tumor tissue and correlated with response in an exploratory fashion, under the hypothesis that navitoclax will have greater activity in cancers with high BCL-XL levels and inadequate apoptotic response.
Original Secondary Outcome Measures  ICMJE
 (submitted: August 10, 2015)
  • Biomarkers of apoptosis such as BCL2-like 1 (BCL-XL) and BCL2-like 11 (apoptosis facilitator) (BIM) levels in tumor tissue [ Time Frame: Baseline ]
    Biomarkers of apoptosis such as BCL-XL and BIM levels will be measured in tumor tissue and correlated with response in an exploratory fashion, under the hypothesis that navitoclax will have greater activity in cancers with high BCL-XL levels and inadequate apoptotic response.
  • Change in plasma concentration of EGFR T790M and other EGFR mutations [ Time Frame: Baseline to up to 2 years ]
    Change in plasma concentration of EGFR T790M and other EGFR mutations will be studied in an exploratory fashion and compared to tumor response on imaging.
  • Objective response rate by RECIST [ Time Frame: Baseline up to 30 days after completion of study drug ]
    Calculated in the 20 patient expansion cohort and compared to the expected response rate of 61% in T790M+ lung cancer.
  • Pharmacokinetics parameters (maximum observed plasma drug concentration, area-under-the concentration-time-curve, Trough drug concentration at steady state, and half-life) of EGFR inhibitor AZD9291 in combination with navitoclax [ Time Frame: Pre-dose, 1, 2, 4, 6, and 8 hours after navitoclax administration (day 1 of courses 1 and 2) ]
    Pharmacokinetic calculations will incorporate consideration of the dosing change in navitoclax between the two measurement days.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer
Official Title  ICMJE A Phase 1B Study of AZD9291 in Combination With Navitoclax in EGFR-Mutant Non-Small Cell Lung Cancer Following Resistance to Initial EGFR Kinase Inhibitor
Brief Summary This phase Ib trial studies the side effects and best dose of osimertinib and navitoclax when given together and to see how well they work in treating patients with previously treated epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer that has spread to other places in the body or has not responded to previous treatment with initial EGFR kinase inhibitor. Osimertinib and navitoclax may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving with osimertinib together with navitoclax may work better in treating EGFR-positive non-small cell lung cancer.
Detailed Description

PRIMARY OBJECTIVES:

I. To determine the safety and tolerability of AZD9291 (osimertinib) in combination with navitoclax in patients with EGFR-mutant non-small cell lung cancer (NSCLC) following resistance to prior EGFR-tyrosine kinase inhibitor (EGFR TKI).

II. To evaluate the feasibility of treatment with AZD9291 plus navitoclax for patients with T790M-mediated acquired resistance to EGFR TKI.

SECONDARY OBJECTIVES:

I. To study the pharmacokinetic profile of the combination of AZD9291 plus navitoclax.

II. To observe and record anti-tumor activity.

CORRELATIVE OBJECTIVES:

I. To study plasma genotype levels as a response biomarker in patients with EGFR-mutant lung cancer.

II. To explore tissue biomarkers of apoptosis and their association with treatment response.

OUTLINE: This is a phase Ib, dose-escalation study followed by a dose-expansion study.

Patients receive navitoclax orally (PO) once daily (QD) on days 1-28 and osimertinib PO QD on days 4-28 (days 1-28 during dose-expansion). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Advanced Lung Non-Squamous Non-Small Cell Carcinoma
  • EGFR Activating Mutation
  • EGFR Exon 19 Deletion Mutation
  • EGFR NP_005219.2:p.G719X
  • EGFR NP_005219.2:p.L858R
  • EGFR NP_005219.2:p.L861Q
  • EGFR NP_005219.2:p.T790M
  • Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
  • Stage III Non-Small Cell Lung Cancer AJCC v7
  • Stage IIIA Non-Small Cell Lung Cancer AJCC v7
  • Stage IIIB Lung Non-Small Cell Cancer AJCC v7
  • Stage IV Non-Small Cell Lung Cancer AJCC v7
Intervention  ICMJE
  • Other: Laboratory Biomarker Analysis
    Correlative studies
  • Drug: Navitoclax
    Given PO
    Other Names:
    • A-855071.0
    • ABT-263
    • BcI-2 Family Protein Inhibitor ABT-263
  • Drug: Osimertinib
    Given PO
    Other Names:
    • AZD-9291
    • AZD9291
    • Mereletinib
    • Tagrisso
  • Other: Pharmacological Study
    Correlative studies
Study Arms  ICMJE Experimental: Treatment (navitoclax, osimertinib)
Patients receive navitoclax PO QD on days 1-28 and osimertinib PO QD on days 4-28 (days 1-28 during dose-expansion). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity
Interventions:
  • Other: Laboratory Biomarker Analysis
  • Drug: Navitoclax
  • Drug: Osimertinib
  • Other: Pharmacological Study
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: October 14, 2015)
50
Original Estimated Enrollment  ICMJE
 (submitted: August 10, 2015)
44
Study Completion Date  ICMJE Not Provided
Estimated Primary Completion Date July 30, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Histologically confirmed non-squamous NSCLC, with incurable advanced or metastatic disease
  • Prior genotyping positive for an EGFR activating mutation (L858R, exon 19 deletion, G719X, L861Q)
  • Progression after prior treatment with an EGFR TKI; in addition to this one prior line of therapy, any additional prior lines of therapy are permitted; prior treatment with a third-generation EGFR TKI is allowed for the dose escalation phase, but is not permitted for the expansion cohort
  • Adequate archival tissue from a biopsy performed after progression of disease on previous EGFR TKI; or willing to undergo a new tumor biopsy prior to registration (for the dose escalation portion only this requirement can be waived if T790M status has already been determined using a local assay)
  • For the dose expansion portion only, patient must: 1) have a tumor which is EGFR-T790M positive and 2) be treatment naive to T790M-directed EGFR TKI (e.g. AZD9291, rociletinib, etc); T790M testing may be done locally or centrally on study, but if done locally, tissue must be available for central confirmation
  • Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
  • Any number of prior therapies are allowed
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%)
  • Patients must have the ability to swallow oral dosage forms
  • Life expectancy of greater than 3 months
  • Leukocytes >= 3,000/mcL
  • Absolute neutrophil count >= 1,500/mcL
  • Hemoglobin >= 8.0 g/dL
  • Platelets >= 100,000/mcL
  • Activated partial thromboplastin time (aPTT), prothrombin time (PT) =< 1.2 x upper limit of normal (ULN)
  • Total bilirubin =< 1.5 x ULN (patients with Gilbert's syndrome may have serum bilirubin > 1.5 x ULN)
  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3.0 x institutional ULN
  • Creatinine =< 2.0 mg/dL
  • Creatinine clearance >= 50 mL/min
  • The effects of AZD9291 and navitoclax on the developing human fetus are unknown; for this reason, women of child-bearing potential and men must agree to use adequate contraception using one of the methods listed below prior to study entry, for the duration of study participation, and for 3 months for women and 6 months for men following the date of the last dose of AZD9291 and/or navitoclax:

    • Total abstinence from sexual intercourse (minimum one complete menstrual cycle prior to study drug administration)
    • Vasectomized male subject or vasectomized partner of female subjects
    • Hormonal contraceptives (oral, parenteral, transdermal or vaginal ring) for at least 3 months prior to study drug administration; if the subject is currently using a hormonal contraceptive, she should also use a barrier method during this study and for 3 months after study completion
    • Intrauterine device (IUD)
    • Double-barrier method: male condom plus diaphragm or vaginal cap with spermicide (contraceptive sponge, jellies or creams)
    • Additionally, male subjects (including those who are vasectomized) whose partners are pregnant or might be pregnant must agree to use condoms for the duration of the study and 6 months following completion of therapy
  • Women of childbearing potential must have a negative urine pregnancy test within 7 days prior to initiation of treatment; women will be considered not of childbearing potential if they are surgically sterile (bilateral oophorectomy or hysterectomy) and/or post-menopausal (amenorrheic for at least 12 months)
  • Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
  • Patients with a prior history of brain metastases are eligible provided:

    • The brain metastases have been treated
    • The patient is asymptomatic from the brain metastases
    • Corticosteroids prescribed for the management of brain metastases have been discontinued at least 7 days prior to registration
    • The brain metastases are stable on pre-registration imaging
  • Patients must have completed last chemotherapy >= 3 weeks or radiotherapy >= 2 weeks prior to receiving study drugs
  • Patients must have recovered from adverse events attributable to previous treatment to =< grade 1, except for alopecia and sensory neuropathy =< grade 2
  • Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

  • Major surgery within 21 days of starting protocol treatment
  • Patients must discontinue previous EGFR-TKI at least 7 days prior to study enrollment
  • Patients who are receiving any other investigational agents
  • Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis requiring steroid treatment, or any evidence of clinically active interstitial lung disease
  • Patients currently receiving (or unable to stop use at least 1 week prior to receiving the 1st dose of AZD9291) medications or herbal supplements known to be potent inhibitors of cytochrome P450, family 2, subfamily C, polypeptide 8 (CYP2C8) and potent inhibitors or inducers of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) are ineligible; patients are eligible if they stop use of these compounds at least 1 week prior to receiving any treatment on this protocol
  • Patients receiving anticoagulation or anti-platelet therapy are excluded due to the risk of thrombocytopenia with navitoclax; excluded agents include heparin or low molecular weight heparin, warfarin, clopidogrel, ibuprofen and other nonsteroidal anti-inflammatory drug (NSAIDS), tirofiban, and other anticoagulants, drugs, or herbal supplements that affect platelet function; administration of heparin to keep subject's infusion lines patent is allowed; low-dose anticoagulation medications that are used to maintain the patency of a central intravenous catheter are allowed; aspirin will not be allowed within 7 days prior to the first dose of navitoclax or during navitoclax administration; however, subjects who have previously received aspirin therapy for thrombosis prevention, may resume a low dose (i.e., maximum 100 mg QD) of aspirin if platelet counts are stable (>= 50,000/mm^3) through 6 weeks of navitoclax administration; all decisions regarding treatment with aspirin therapy will be determined by the investigator in conjunction with the medical monitor
  • Patients with an underlying condition predisposing them to bleeding or currently exhibiting signs of clinically significant bleeding
  • Patients with a recent history of non-chemotherapy-induced thrombocytopenic-associated bleeding within 1 year prior to the first dose of study drug
  • Patients with a significant history of cardiovascular disease (e.g., myocardial infarction [MI], thrombotic or thromboembolic event in the last 6 months)
  • Any of the following cardiac criteria:

    • Mean resting corrected QT interval (QTc using Frederica's formula [QTcF]) > 470 msec
    • Any clinically important abnormalities in rhythm, conduction or morphology of resting electrocardiogram (ECG) (e.g., complete left bundle branch block, third degree heart block, second degree heart block)
    • Congenital long QT syndrome or family history of long QT syndrome
  • Patients with active malignancies other than NSCLC or prior curatively treated malignancy at high risk of relapse during the study period with the exception of localized squamous or basal cell skin cancers
  • Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, gastrointestinal disease limiting absorption of AZD9291 such as a malabsorption syndrome or inflammatory bowel disease or psychiatric illness/social situations that would limit compliance with study requirements
  • Pregnant women are excluded from this study because AZD9291 and navitoclax have the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with AZD9291 and navitoclax, breastfeeding should be discontinued if the mother is treated with AZD9291 and navitoclax
  • History of hypersensitivity to AZD9291 (or drugs with a similar chemical structure or class to AZD9291) or any excipients of these agents
  • Patients with human immunodeficiency virus (HIV) on antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with AZD9291
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02520778
Other Study ID Numbers  ICMJE NCI-2015-01270
NCI-2015-01270 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
16-714
9903 ( Other Identifier: Dana-Farber - Harvard Cancer Center LAO )
9903 ( Other Identifier: CTEP )
UM1CA186709 ( U.S. NIH Grant/Contract )
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party National Cancer Institute (NCI)
Study Sponsor  ICMJE National Cancer Institute (NCI)
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Geoffrey R Oxnard Dana-Farber - Harvard Cancer Center LAO
PRS Account National Cancer Institute (NCI)
Verification Date February 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP